Andrew Nunn, Senior Scientist & Professor of Epidemiology
Andrew Nunn joined the MRC’s Tuberculosis & Chest Diseases Unit as a statistician in 1966. During the next 20 years he was directly involved in the design, conduct and analysis of the programme of trials conducted under the leadership of Professors Wallace Fox and Denny Mitchison in East Africa, Hong Kong and Singapore which led to the worldwide adoption of short course chemotherapy for tuberculosis.
Following the closure of that unit he joined the MRC’s Uganda AIDS Programme which researched the dynamics of the HIV epidemic in a rural African environment. On his return to the UK he became head of the Division Without Portfolio within the newly formed MRC Clinical Trials Unit with responsibility for developing trials in neglected areas.
Currently, he is an investigator and senior statistician on three international Phase III trials of tuberculosis treatment one of which, STREAM, is the first Phase III trial in multidrug-resistant TB.
Nunn AJ, Phillips PP, Meredith SK, Chiang C-Y, Conradie F, Dalai D, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. New England Journal of Medicine. 2019;380(13):1201-13.
Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. The Lancet. 2017;389(10079):1630-8.
Phillips PP, Mendel CM, Burger DA, Crook AM, Nunn AJ, Dawson R, et al. Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials. BMC Medicine. 2016;14(1):19.
Rahman NM, Pepperell J, Rehal S, Saba T, Tang A, Ali N, et al. Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion The TIME1 Randomized Clinical Trial. Jama-J Am Med Assoc. 2015;314(24):2641-53.
Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PPJP, Nunn AJ. Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis. N Engl J Med. 2014; Epub 2014/09/10
Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014; 371(17):1599-1608
- Treatment of drug sensitive and multidrug-resistant TB
- Trials in neglected disease areas
- Trials in developing countries
- Non-inferiority trials
- Multiple sclerosis and pain management
- Respiratory disease